Last reviewed · How we verify
Cefazolin Injection
At a glance
| Generic name | Cefazolin Injection |
|---|---|
| Also known as | Four Doses IV Cefazolin |
| Sponsor | Abdul El-Rabbany |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (PHASE4)
- IO Vancomycin Spine (PHASE2, PHASE3)
- Antibiotics for Prevention of Infection Following Orthognathic Surgery (PHASE4)
- Comparison of a Morphomic-Based to the Standard-of-Care-Based Cefazolin Dose for Antimicrobial Prophylaxis (PHASE4)
- IO Vancomycin Into the Medial Malleolus vs IV Administration in Revision TKA (NA)
- A Multidisciplinary Perioperative Pain Management (NA)
- Pharmacokinetics Study of Cefazolin in Hemodialysis (CEFAZODIAL) (PHASE4)
- Antibioprophylaxis for Excision-graft Surgery in Burn Patient (A2B-TRIAL) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefazolin Injection CI brief — competitive landscape report
- Cefazolin Injection updates RSS · CI watch RSS
- Abdul El-Rabbany portfolio CI